

PRODUCT AND PROCESS

The present invention relates to a β -galactosidase with transgalactosylating activity capable of converting lactose to a mixture of oligosaccharides which are β -linked and
5 unexpectedly produces the α -linked disaccharide α 1-6 galactobiose. In particular it relates to a β -galactosidase isolated from a recently discovered strain of *Bifidobacterium bifidum*.

The invention particularly relates to DNA sequences encoding the isolated β -galactosidase enzyme, to the enzyme encoded by such a DNA sequence and to a host cell
10 comprising the DNA sequence or a recombinant vector incorporating the DNA sequence. The invention also relates to the use of the enzyme encoded by a DNA sequence, or of the host cell containing a DNA sequence or recombinant vector, to produce oligosaccharides.

Bifidobacteria naturally colonise the lower intestinal tract, an environment which is
15 poor in mono and disaccharides since such sugars are preferentially consumed by the host and microbes present in the upper intestinal tract. In order to survive in the lower intestinal tract bifidobacteria produce various kinds of exo- and endoglycosidases in surface bound and/or extracellular forms, by which they can utilise diverse carbohydrates.

20 Besides hydrolase activity, some enzymes from bifidobacteria show transferase activity. This transglycosylation activity of glycosidases is extensively used for the enzymatic synthesis of various oligosaccharides, which have proven to act as bifidobacteria growth promoting factors.

25 It is known that members of bifidobacteria produce β -galactosidase enzymes that are involved in the bacterial metabolism of lactose. Møller, P.L. et al in Appl & Environ. Microbial., (2001), 62, (5), 2276-2283 describe the isolation and characterisation of three β -galactosidase genes from a strain of *Bifidobacterium bifidum*. They found that all three β -galactosidases were able to catalyse the formation of beta-linked galactooligosaccharides
30 by transgalactosylation.

Dumortier et al in Carbohydrate Research, 201, (1990), 115-123 described the formation of beta-linked oligosaccharides by a transgalactosylation reaction during lactose hydrolysis with *Bifidobacterium bifidum* DSM 20456. Their analysis of the structure of the mixture of oligosaccharides produced showed that the linkages were β -(1 $\rightarrow$ 3), β -(1 $\rightarrow$ 6) and β -(1 $\rightarrow$ 4)-D-galactosyl linkages. Dumortier suggested that compounds produced by *Bifidobacterium bifidum* are involved in the adherence of bacteria in the large intestine.

A strain of *Bifidobacterium bifidum* has been found that is capable of producing a galactosidase enzyme activity that converts lactose to a novel mixture of galactooligosaccharides which unexpectedly contains up to 35% of disaccharides including galabiose (Gal (α 1-6) - Gal). This disaccharide is known (see Paton, J C and Paton, A W (1998), Clin. Microbiol. Revs., 11, 450-479; Carlsson, K A (1989), Ann. Reviews Biochem., 58, 309-350) to be an antiadhesive capable of preventing the adhesion of toxins, eg Shiga toxin and pathogens such as *E. coli*, to the wall of the gut.

This strain of *B bifidum* was deposited under accession number NCIMB 41171 at the National Collection of Industrial & Marine Bacteria, Aberdeen, UK on 31 March 2003. It is also described in UK Patent No 2 412 380.

It has now been found that this strain of *B bifidum* produces several β -galactosidases, one of which unexpectedly exhibits α -galactosyltransferase activity. This enzyme produces a number of different oligosaccharides which are β -linked, but it also produces the α -linked disaccharide galabiose.

According to the invention there is provided a DNA sequence which encodes a protein with an amino acid sequence as given in SEQ. ID NO: 2. The DNA sequence is given in SEQ. ID NO: 1.

According to a second aspect of the invention there is provided an enzyme encoded by a DNA sequence as defined above. Such an enzyme may comprise the amino acid sequence given in SEQ. ID NO: 2.

5 According to a third aspect of the invention there is provided a recombinant vector, preferably an expression vector, comprising a DNA sequence as defined above. Such a vector may be incorporated into a host cell such as a bacterial, yeast or fungal cell. Alternatively, the DNA sequence may be incorporated into such a host cell. A suitable host
10 cell may be selected from *Bifidobacterium*, *Lactococcus*, *Lactobacillus*, *Bacillus* for example *Bacillus subtilis* or *Bacillus circulans*, *Escherichia* and *Aspergillus* for example *Aspergillus niger*.

Using lactose as a substrate, the enzyme encoded by a DNA sequence as defined above produces a mixture of disaccharides comprising Gal (β 1-3) Glc, Gal (β 1-3) Gal,
15 Gal (β 1-6) Gal and Gal (α 1-6) Gal. Also present in the mixture of oligosaccharides are trisaccharides Gal (β 1-6) Gal (β 1-4) Glc, Gal (β 1-3) Gal (β 1-4) Glc, tetrasaccharide Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc and pentasaccharide Gal (β 1-6) Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc.

20 The enzyme or the host cell as described above may be used to produce a mixture of disaccharides, including Gal (α 1-6) Gal (galabiose) which may form part of a product for improving gut health. Such a product may be selected from the group consisting of dairy products (for example liquid milk, dried milk powder such as whole milk powder, skimmed
25 milk powder, fat filled milk powders, whey powders, baby milks, baby formula, ice cream, yoghurt, cheese, fermented dairy products), beverages such as fruit juice, infant foods, cereals, bread, biscuits, confectionery, cakes, food supplements, dietary supplements,

synbiotic comestible products, prebiotic comestible products, animal feeds, poultry feeds or indeed any other food or beverage.

Alternatively, the oligosaccharides so produced may be used for the preparation of a medicament for example in table or capsule form for preventing the adhesion of pathogens or toxins produced by pathogens to the gut wall. The medicament may be administered to a patient, for example following a course of antibiotic treatment, which often alters or even destroys the normal healthy gut flora.

According to yet a further aspect of the invention there is provided a process for producing an enzyme as defined above which comprises culturing a host cell as defined above in a suitable culture medium under conditions permitting expression of the enzyme and recovering the resulting enzyme from the culture.

The invention is also directed to a process for producing a mixture of oligosaccharides, including the disaccharide Gal (α 1-6) - Gal (galabiose), which comprises contacting the enzyme as defined above or a host cell as defined above with a lactose-containing material under conditions that lead to the formation of the oligosaccharide mixture.

Suitable lactose containing material may be selected from commercially available lactose, whole milk, semi-skimmed milk, skimmed milk, whey and fat-filled milk, whey permeate. Such milk products may be obtained from cows, buffaloes, sheep or goats. Fat-filled milk is defined as whole milk that has been skimmed to remove the dairy fat, which is subsequently replaced by the addition of vegetable fat or oil.

Brief Description of the Drawings

Figure 1 shows the nucleotide sequence (SEQ. ID NO: 1) of *Bifidobacterium bifidum* β -galactosidase of the invention; and

Figure 2 shows the amino acid sequence (SEQ. ID NO: 2) corresponding to the nucleotide sequence of Figure 1.

Figure 3 is a graph showing the time course reaction during galactooligosaccharide synthesis with the β -galactosidase and 40% (w/w) lactose in 0.1M phosphate buffer at pH 6.0 as substrate; and

Figure 4 shows a high performance anion exchange chromatogram of the galactooligosaccharide mixture synthesized by the β -galactosidase from *B. bifidum* NCIMB 41171 using 40% (w/w) lactose in 0.1M phosphate buffer at pH 6.0 as substrate. (Glc = glucose, Gal = galactose, Lac = lactose, α (1-6) galactobiose, DP = degree of polymerisation).

Genomic DNA was isolated from the *Bifidobacterium bifidum* strain (NCIMB 41171) using the method of Lawson *et al.* (1989) *Fems Microbiol* Letters, **65**, (1-2), 41-45. The DNA was digested with restriction enzymes and fragments having a maximum size of 15 kbp were ligated with pSP72 vector which had been digested with the same restriction enzymes. *E. coli* cells were transformed with a vector containing insertions consisting of PstI, Eco RI, Bam HI, KpnI, SmaI or HindIII digested chromosomal DNA from the *B. bifidum*. Clones with β -galactosidase activity were selected on Luria Bertani agar plates containing p-nitrophenyl, X- β -Gal (5-bromo-4-chloro-3-indolyl- β -D-galactoside) and isopropyl- β -D-thiogalactoside (IPTG). Ligation mixtures with Bam HI chromosomal DNA gave rise to seven β -galactosidase positive clones, one of which is identified as pB1.

DNA sequencing of the inserted DNA fragment B1 was performed using the dideoxy chain-termination method of Sanger (Russel P., 2002 iGenetics, Pearson Education, Inc., San Francisco, 187-189) using the BigDye Terminator V.3.0 cycle sequencing kit (Applied Biosystems, USA). The DNA sequence of B1 is shown in Figure 1 (SEQ. ID NO: 1).

The open reading frame (ORF) was located by using the ORF finder from NCBI (National Center of Biotechnology Information). The nucleotide sequence of Figure 1 was translated in all six possible reading frames and one open reading frame of 1052 amino acids encoding a putative β -galactosidase was identified. The translation is shown in Figure 2 (SEQ. ID NO: 2).

The present invention will be further described by way of reference to the following example.

Example 1

Materials and Methods

All chemicals and media preparations used throughout this study were obtained from Sigma (Dorset, UK), Invitrogen (Paisley, UK), Oxoid (Basingstoke, UK), Qiagen (West Sussex, UK) and Promega (Southampton, UK).

Bacterial Strains

The *Bifidobacterium bifidum* strain (NCIMB 41171) was maintained on cryogenic beads in Microbank tubes at -70°C. For later experiments, the strain was revived on Wilkinson Chalgren (WC) agar (Oxoid, UK) and TPY medium (trypticase phytone yeast extract medium) and grown anaerobically (CO₂ and N₂ composition 80% and 20% respectively) at 37°C for 48 hours. The colony morphology and the absence of contamination were tested by gram staining.

E. coli strains

Escherichia coli strain DH5a used in this study was commonly incubated under aerobic conditions at 37°C in Luria Bertani (LB) agar or broth (Sambrook J. and Russell W. D. (2001). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, New York) and when necessary was supplemented with antibiotics (100µg/ml ampicillin and/or 15µg/ml chloramphenicol) and 40µl of 2% X-β-Gal, 7µl of 20% (isopropyl-β-D-thiogalactoside) IPTG which were applied on the surface of a pre-made 90mm agar plate.

E. coli DH5a strain (Invitrogen, Paisley, UK) (genotype: F⁻ φ80lacZΔM Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(r_k⁻, m_k⁻) phoA supE44 thi-1 gyrA96 relA1λ⁻) is an α-galactosidase positive strain and was used in expression experiments and for other genetic manipulations.

Genomic DNA Extraction from *Bifidobacterium bifidum*

Genomic DNA was isolated from the *Bifidobacterium bifidum* strain (NCIMB 41171) using the following method in which chromosomal DNA was prepared from cell pellet harvested from 100 ml of WC anaerobe broth. The cells were resuspended in 10 ml
 5 TES buffer (10 mM Tris-HCl, 10 mM EDTA, 10 mM NaCl, pH8) and treated with 200 µl of lysozyme/mutanolysin mixture (4:1, lysozyme 10 mg/ml mutanolysin 1 mg/ml) for 30 minutes at 37°C. The cells were then treated with 200 µl of proteinase K (at 20 mg/ml) and 200 µl of RNase (both 10 mg/ml) mixed and incubated for one hour at 65°C. Finally the
 10 cells were treated with 2 ml of 10% SDS and incubated for 15 minutes at 65°C. 12 ml of phenol/chloroform were added and the extraction was repeated until the water phase could easily be separated from the interphase. The genomic DNA was precipitated with isopropanol and resuspended in 10 mM Tris-HCl – 1 mM EDTA (pH8). The genomic DNA was then digested with restriction enzymes, ligated into pSP72 digested with the same enzymes and treated with alkaline phosphatase. Digestion of *B. bifidum* genomic
 15 DNA was performed using *EcoRI*, *PstI*, *BamHI*, *SmaI* and *KpnI*. Ligation mixtures were used to transform *E. coli* DH5a and β-galactosidase positive clones were identified as blue colonies on X-Gal-containing plates.

20 Vector DNA Preparation

The vector used for cloning and expression throughout this study was the pSP72 (Promega, UK) (Krieg, P.A. and Melton, D.A. (1987). In vitro RNA synthesis with SP6 RNA polymerase. *Methods in Enzymology*. 155: 397-415).

25 This vector was chosen because of the lack of complementing activity of the α-fragment of β-galactosidase which is not encoded in pSP72. This vector does not carry the short segment of *E. coli* DNA containing the regulatory sequence and the coding information for the first 146 amino acids of β-galactosidase which in combination with *E. coli* strains (ie DH5a) which express the carboxy-terminal portion of this β-galactosidase is
 30 giving an active β-galactosidase (α-complementation).

The vector was digested with the following restriction enzymes: *Pst*I, *Bam*HI, *Hind*III, *Sma*I, *Kpn*I and *Eco*RI according to the manufacturer's instructions using a tenfold excess of enzyme over DNA (enzyme units : μ gr DNA equal to ten units of enzyme per one μ gr of plasmid DNA or ten enzyme units per 0.5 pmol of plasmid DNA). After enzyme
 5 heat inactivation (20 min at 65°C) the restriction patterns were analysed by horizontal gel electrophoresis analysis. The presence of a single fragment in the gel indicated the complete vector digestion and the single restriction digestion of it.

The sufficient digestion of the vector was tested also by transforming unligated
 10 molecules into competent *E. coli* DH5a cells. The number of formed colonies on LB agar plates supplemented with ampicillin (100 μ gr/ml) was an indicator of the undigested molecules and the expected background during the subsequent experiments.

The vectors were further dephosphorylated with calf intestinal alkaline phosphatase
 15 CIAP (Promega, Southampton, UK) according to the manufacturer's instructions. The efficiency of the treatment was tested by self ligation (with Bacteriophage T4 DNA ligase according to manufacturer instructions) following transformation into DH5a cells. The number of formed colonies showed the number of recirculised molecules (non cloned vector) and a subtraction of the above with the formed colonies without CIAP vector
 20 treatment shown the number of non dephosphorylated vectors.

Genomic DNA Library Construction

Genomic DNA was partially digested with six restriction enzymes that recognise frequently occurring hexa-nucleotide sequences within prokaryotic DNA. *Eco*RI, *Bam*HI,
 25 *Pst*I, *Kpn*I, *Sma*I and *Hind*III are type II restriction endonucleases specifically recognizing the sequences 5'G/AATTC'3, 5'G/GATCC'3, 5'CTGCA/G'3 , 5'GGTAC/C3', 5'CCC/GGG3' and 5'A/AGCTT3' respectively, and make double-strand breaks within these sequences generating 5'overhangs of four nucleotides, AATT, GATC, AGCT for *Eco*RI, *Bam*HI and *Hind* III respectively, and 3'overhangs, ACGT,GTAC for *Pst*I and *Kpn*I
 30 respectively and blunt ends for *Sma*I.

All these enzymes were active and able to cleave DNA only in the presence of divalent magnesium ions. These ions were the only required cofactor.

Restriction Digestion of DNA.

- 5 All restriction digestions of the genomic DNA samples were incubated for 2 hours at 37°C and finally heat inactivated at 65°C for 20 minutes. The reactions were then cooled at room temperature and the appropriate amount of loading buffer was added, followed by gentle mixing with a sealed glass capillary. The solutions then were loaded into wells of a 0.8% agarose gel (power supply 4-5volts/cm for 14-16 hours) and the size of the digested
- 10 DNA was estimated with that of 1kbp DNA standards (Promega, UK) (Sambrook J. Molecular Cloning: A Laboratory Manual (2002)).

Purification of the fragments generated after restriction digestion.

- Fragment purification from the reaction mixtures and the agarose gels was done by
- 15 using the QIAEX gel extraction kit from Qiagen (West Sussex, UK). Protocols are described with details in the manufacturer's manual.

DNA Ligation and Transformation

- After purification of the DNA fragments with the Qiaex gel extraction kit, they were ligated with CIAP-treated pSP72 vector. For ligation, appropriate amounts of DNA were
- 20 transferred to sterile 0.5 ml microfuge tubes as shown in Table 1.

Tube	DNA
A	Vector (15 fmoles [~ 29.7 ng])
B	Vector (15 fmoles ~29.7ng DNA) plus insert (foreign 15 fmoles ~69.3ng)
C	pUC control (0.056 fmoles [~100 pg])
The molar ratio of plasmid DNA vector to insert DNA fragment should be ~1:1 in the ligation reaction. The final DNA concentration should be ~10ng/μl.	

- Table 1:** Ligation mixtures. Tube A shows the number of self-ligated vector DNA which must be subtracted from the total number of transformants after transformation. Tube B
- 25 shows the ligation of the vector with the DNA fragments and tube C shows the control in order that the transformation efficiency to be calculated.

Before each ligation the DNA fragments were warmed at 45°C for 5 minutes to melt any cohesive termini that reannealed during fragment preparation. A molar ratio of vector:insert DNA of 1:1 was chosen for all ligation reactions and the reaction assembly was done according to Promega's instructions.

5

To tubes A and B 1.0 µl of 10x ligation buffer and 0.5 Weiss units of T4 DNA ligase (Promega, UK) were added and the ligation volume was adjusted to 10 µl with molecular biology grade water. To tubes C 1.0 µl of 10x ligation buffer were added and the ligation volume was adjusted to 10 µl with molecular biology grade water.

10

DNA fragments were added to the tubes together with the water and then warmed to 45°C for 5 minutes to melt any cohesive termini that were reannealed during preparation. The DNA was chilled to 0°C before the remainder of the ligation reagents were added and the reaction mixtures were incubated overnight at 16°C (Sambrook and Russell, 2001).

15

After ethanol precipitation and purification of the ligated fragments (in order to remove the ligation mixture which cause reduction of the transformation efficiency) transformations were performed according to Hanahan instructions. ~50ng of ligated DNA in 5µl solution was added to 100µl of competent E.Coli DH5a cells. After heat treatment and expression of the ampicillin resistance gene the cells were spreaded over the surface of LB plates containing ampicillin (100µgr/ml), X-β-Gal (40µl of 2% X-β-Gal) and IPTG (7µl of 20%IPTG).

20

The number of transformants from each ligation reaction was measured. The number of transformants commonly obtained from tube C was 2×10^5 - 1×10^6 cfu/µg whereas from tube A was 500-600 cfu/µg. The number of transformants in tube A was an indication of the efficient treatment of the vector DNA. The number of transformants in tube B was in a range from 2 - 4×10^4 cfu/µg.

25

Number of Transformants

Ligation mixtures with *Pst*I chromosomal DNA gave rise to 13 β -galactosidase positive clones out of ~2500 screened transformants whereas with *Bam*HI gave rise to 7 positive clones (~1500 scr. transformants), *Eco*RI gave rise to 3 positive clones (~1300 scr. transformants), *Kpn*I gave rise to 7 positive clones (~2000 scr. transformants), *Sma*I gave rise to 3 positive clones (~1600 scr. transformants) and *Hind*III gave rise to 2 positive clones (~1200 scr. transformants).

Positive Clone Digestion

In order to identify the different β -galactosidase genes, the plasmids isolated from the positive clones were digested according to the following table.

	Samples	Enzymes
1 st Digestion	pB1, pB2, pB3, pB4, pB5, pB6, pB7	<i>Bam</i> HI
2 nd Digestion	pP1, pP2, pP3, pP4, pP5, pP6, pP7, pP8, pP9, pP10, pP11	<i>Pst</i> I
3 rd Digestion	pP12, pP13, pP14	<i>Pst</i> I
4 th Digestion	pE1, pE2, pE3	<i>Eco</i> RI
5 th Digestion	pP1, pP12, pB1, pP2, pE1, pE2, pE3.....	<i>Pst</i> I and <i>Eco</i> RI
6 th Digestion	pS1, pS2, pS3	<i>Sma</i> I
7 th Digestion	pP1, pP12, pB1, pP2, pS1, pS2, pS3	<i>Pst</i> I and <i>Sma</i> I
8 th Digestion	pK1, pK2, pK3, pK4, pK5, pK6, pK7	<i>Kpn</i> I
9 th Digestion	pP1, pP12, pB1, pP2, pK1, pK2, pK3, pK4, pK5, pK6, pK7	<i>Pst</i> I and <i>Kpn</i> I
The first letter (p) indicates plasmid and the insert gene whereas the second letter (P,B,E,S,K) indicates the restriction enzyme that was used for isolation of the respective clone from the genomic DNA.		

Gel electrophoresis analysis of the generated fragments after digestion was shown that plasmids pB1, pP1, pP2 and pP11 each have an insert which encodes a different β -galactosidase. The clones containing pB1 was used for further analysis.

DNA Sequencing

DNA sequencing was performed with the dideoxy chain-termination method of Sanger by using the BigDye Terminator v.3.0 cycle sequencing kit (Applied Biosystems,

USA) and analysed with the ABI Prism 3100, a fluorescence-based DNA analysis system incorporating capillary electrophoresis.

The 5'- and 3'- ends of the inserted DNA fragments were sequenced with vector specific primers. The inserts were further sequenced by using the Genome Priming System (GPS-1) (New England Biolabs, UK). GPS-1 is a TN7 transposon-based in vitro system which uses TnsABC Transposase to insert Transposon randomly into the DNA target. The donor: target DNA mass ratio of 1:4 was used according to the manufacturer instructions. The number of isolated plasmids for sequencing after insertion of the Transprimer into the target plasmid was 25. This number was calculated according to the manufacturer instructions and it assumes a 5-fold depth of coverage.

For plasmid pB1 insertion of a ≈ 1699 bp's transposon-insert at position 973bp downstream of the multiple- cloning site of the vector used completely eliminated the β -galactosidase activity indicating that the start codon was positioned between the vector MCS (multiple cloning site) and the transposon site, whereas insertion of the insert at position 841bp downstream of the MCS led to the formation of an active β -galactosidase indicating that the start codon exists between 841bp and 973bp downstream of the MCS. The enzyme activity was eliminated completely with insertion of the insert at a position 3565bp downstream of the MCS indicating that the stop codon is downstream of this position. Moreover insertions at positions 1239bp, 1549bp, 1683bp, 1832bp, 2108bp, 2189bp, 2270bp, 2340bp, 2414bp, 2574bp, 2648bp, 2734bp, 2807bp and 3410bp completely eliminate the enzymatic activity.

The sequencing reaction mix contained approximately 400-600ng plasmid DNA, 3.2pmol of primer solution and 4 μ l of BigDye Terminator solution.

Open Reading Frame Identification

The open reading frame (ORF) of B1 was located by using the ORF finder from NCBI. The bacterial genetic code was used and the frame length was determined to be 100bp. The nucleotide sequence was translated in all six possible frames and an open

reading frame of 1052 amino acids encoding a putative β -galactosidase was identified (The translation is shown in Figure 2).

Example 2

5

Synthesis with the β -galactosidase cloned enzyme isolated from *Bifidobacterium bifidum* NCIMB 41171 in *E. coli* host (strain DH5a)

The following described synthesis, unless otherwise stated, was performed with the whole *E. coli* DH5a host cells after treatment of the *E. coli* biomass (collected by centrifugation at 10,000 g) with toluene at a concentration of 2000 ppm in order to increase cell permeability and also to render the cells non-viable by destroying their cytoplasmic membrane. The *E. coli* biomass was prepared as described in Example 1 under “*E. coli* strains”.

Synthesis with cloned enzyme

Synthesis with β -galactosidase was performed at a substrate concentration of 40% (w/w) initial lactose concentration. The synthesis solution was prepared in 0.1 M phosphate buffer at pH 6.8 (or 0.1M citrate buffer pH 6.2 or potassium phosphate buffer pH 6.8)). Synthesis was performed at 40°C in shaking waterbath at 150 rpm. The pH optimum for the specific enzyme was chosen based on activity measurements (using o-nitrophenyl- β -D-galactopyranoside as substrate) of a specific enzymatic preparation at varying pH values.

For galactooligosaccharide synthesis 5 ml of an *E. coli* DH5a cell suspension (with an activity of 2.2 U/ml) were centrifuged (at 10,000 g) to collect the biomass and the supernatant was discarded. This biomass was re-suspended with 10 g of 40% (w/w) substrate solution in order to perform the synthesis.

The concentrations of the different sugars present in the mixture during synthesis are shown in Figure 3. High performance anion exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD) chromatograms of galactooligosaccharide mixtures synthesized by the β -galactosidase cloned from *B. bifidum* NCIMB 41171 are

shown in Figure 4. The galactooligosaccharide mixture sugar concentrations at the optimum synthesis time point are shown in table 1.

- 5 **Table 1.** Carbohydrate composition of galactooligosaccharide synthesis at 40 % (w/w) initial lactose concentration at the time point where maximum oligosaccharide concentration was observed.

Synthesis Init. Subst.	GOS DP $\geq$ 3	GOS DP=2	Lac	Glc	Gal
% (w/w)	Concentration (% of total sugars)				
40	20.45	27.64	12.73	25.90	13.28

10

Lac: Lactose, Glc: glucose, Gal: galactose, DP: degree of polymerisation

Claims

1. A DNA sequence which encodes a protein with an amino acid sequence as given in SEQ. ID. NO: 2.

2. The DNA sequence according to Claim 1, wherein the sequence is given in SEQ. ID NO: 1.

3. An enzyme encoded by a DNA sequence of Claim 1 or Claim 2.

4. An enzyme comprising an amino acid sequence according to SEQ. ID NO: 2.

5. A β -galactosidase having the sequence as defined in SEQ. ID NO: 2.

6. A recombinant vector comprising a DNA sequence of Claim 1 or Claim 2.

7. The vector according to Claim 6, wherein said vector is an expression vector.

8. A host cell comprising a DNA sequence of Claim 1 or Claim 2.

9. A host cell comprising the vector of Claim 6 or Claim 7.

10. The host cell according to Claim 8 or Claim 9, wherein said cell is a bacterial cell, a yeast cell or a fungal cell.

11. The host cell according to Claim 10, wherein said cell is selected from the group consisting of Bifidobacterium, Lactococcus, Lactobacillus, Escherichia, Bacillus and Aspergillus.

12. The host cell according to Claim 11, wherein the cell is selected from the group consisting of *Bifidobacterium bifidum*, *Bacillus subtilis*, *Bacillus circulans* and *Aspergillus niger*.
13. Use of an enzyme of any one of Claims 3 to 5, or a cell of any one of Claims 8 to 12, for producing a mixture of oligosaccharides.
14. Use according to Claim 13, wherein the mixture comprises disaccharides Gal (β 1-3) Glc, Gal (β 1-3) Gal, Gal (β 1-6) Gal and Gal (α 1-6) Gal.
15. Use according to Claim 13 or Claim 14, wherein the mixture comprises trisaccharides Gal (β 1-6) Gal (β 1-4) Glc, Gal (β 1-3) Gal (β 1-4) Glc, tetrasaccharide Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc, and pentasaccharide Gal (β 1-6) Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc.
16. Use of an enzyme of any one of Claims 3 to 5, or a cell of any one of Claims 8 to 12, for producing a mixture of oligosaccharides to be part of a product selected from the group consisting of dairy products, such as liquid milk, dried milk powder, baby milks, baby formula, ice cream, yoghurt, cheese, fermented dairy products, beverages such as fruit juice, infant foods, cereals, bread, biscuits, confectionary, cakes, food supplements, dietary supplements, probiotic comestible products, prebiotic comestible products, animal feeds, poultry feeds and medicaments.
17. Use according to Claim 16, wherein the mixture comprises disaccharides Gal (β 1-3) Glc, Gal (β 1-3) Gal, Gal (β 1-6) Gal and Gal (α 1-6) Gal, trisaccharides Gal (β 1-6) Gal (β 1-4) Glc, Gal (β 1-3) Gal (β 1-4) Glc, tetrasaccharide Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc, and pentasacchride Gal (β 1-6) Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc.

18. Use of a host cell of any one of Claims 8 to 12, for producing a product selected from the group consisting of dairy products, such as liquid milk, dried milk powder, baby milks, baby formula, ice cream, yoghurt, cheese, fermented dairy products, beverages such as fruit juice, infant foods, cereals, bread, biscuits, confectionary, cakes, food supplements, dietary supplement, probiotic comestible product, prebiotic comestible product, animal feeds, poultry feeds and medicaments.

19. A process for producing an enzyme of any one of Claim 3 to 5 comprising culturing a host cell of any one of Claims 10 to 14 in a suitable culture medium under conditions permitting expression of said enzyme and recovering the resulting enzyme from the culture.

20. A process for producing a mixture of oligosaccharides comprising disaccharides Gal (β 1-3) Glc, Gal (β 1-3) Gal, Gal (β 1-6) Gal and Gal (α 1-6) Gal, trisaccharides Gal (β 1-6) Gal (β 1-4) Glc, Gal (β 1-3) Gal (β 1-4) Glc, tetrasaccharide Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc, and pentasacchride Gal (β 1-6) Gal (β 1-6) Gal (β 1-6) Gal (β 1-4) Glc, said process comprising contacting an enzyme of any one of Claims 3 to 5 or a host cell of any one of Claims 8 to 12 with a lactose-containing material.

Sequence Listing_ST25
SEQUENCE LISTING

<110> LINDSAY, Clare L
<120> Product and Process
<130> 13906WO:GH
<150> GB 0601901.2
<151> 2006-01-31
<160> 2
<170> PatentIn version 3.4
<210> 1
<211> 7281
<212> DNA
<213> Bifidobacterium bifidum

<220>
<221> gene
<222> (1)..(7281)

<400> 1
ggatccggtg aacgcgccga ggcggtgta cgtgctgcgc tcgtgcgagt cggaggagat 60
cgcggggatc atgccccagt aggagatgtc ggcgagcgag tagatcacgt cgagcaggat 120
gaacacgatg acgaacagga ccatgaacac gccggtgttc acatccacga ggccgaacag 180
gccggtgaac accatgatca gcaggatgcc aggcacgatg ccgccaatga actgccacgg 240
gcggaaccgg cccagcggg tgttcgtgtt gtccacgagg ttgccgagca gcgggtcgag 300
aaagatctcc gcgatgcgga tgaccaccac gagtccggtg atcaccgcga tgaggcgttt 360
ggcaagcgtc ttgtccacgt cgatgaacag cgcggtggtc acgaacgtga tgaagaacgt 420
gctcattgtg ttgtagaacg cggcctggcc caggttaccg aatgcgtatg cgatcttctg 480
acccgtgttc cgcgtgggct gcggccttcc ggtcgtttcc gtgtgttgtg tggtaggattc 540
gctcatggtg tggtaggctc cttgcgacct gtaaagaatc cgtgcgcgtg aaccgctccg 600
atcccgcaaa gcgtgagtat agaactttct tgaaaaagta gaaaactata ccgctgtctg 660
caaatcatgc caacgttctg caaccggcac tccgtgtgga tgagtaagggt ttgaagcctg 720
cttgatgtgc ttgaatctta agaaatccac gtattctgca tgttgaggc cttgtgccgc 780
gaaatgctgg aaagaatttg cgcaatcaag taacaatatt tatccttggt gtacaaggaa 840
cccgattcaa cgaggttccc tctgctggc ggcaacgacg cgacgcaatc cgatgcgaaa 900
gcgaggacat catgaacaca accgacgatc agcggaagaa cggcgatccg atcgtctccc 960
cgtccatacc gacgacggca tggctcgccg acccgcgctg gtacgagggt caccggctcg 1020
acgcccattc cgatcatgcg tgctgggtctc gctccccagt cgacggcgag agcacgaatc 1080
tcaggcagag cttgacggc gaatggcggg tccgcgtcga gacggcgccg acgggcccgtt 1140
tccccgatgg gacgagcgac gggccggact ggatcagcga cgtgtcgcct ctgttcgccg 1200
cgcccggtt cgacgattcg tcgttctcac gcgtgcagggt gccctcgcat ctggagactg 1260

Sequence Listing_ST25

cggggctgct	tgccccgcag	tacgtgaacg	tgagtagacc	atgggacgga	catgaggacc	1320
cgaaggcccc	ggccatcccc	gagcatggcc	atgtggcggg	ctaccggcgc	gagttcgacg	1380
cggatggcga	agtcgcccag	gccgtgcgcg	aagggcgccc	ggtagcgctt	accttccagg	1440
gcgcggccac	agccatctac	gtgtggctca	acggctcggt	cgttggctac	gccgaggact	1500
ccttcacgcc	cagcgagttc	gacgtgacgg	acgcgatcaa	ggtaggacgg	aacgtgctgg	1560
cggtcgtctg	ctacgagtat	tcgagcgcca	gctgggttga	ggatcaggac	ttctggcgtc	1620
tgacggcct	gttccgctcc	gtcgaactca	acgcgaggcc	cgccgcccac	atcgccgacc	1680
tccatgccga	cgccgactgg	gatctcgcca	catcaagggg	ttcgctctcg	ctggatgtgc	1740
tgatcgacgg	tgccgcgaac	gccgcgacgg	tcgacttcgc	actgtgggac	aagaacggca	1800
ccatcgctctg	gcacaccgcc	acgaaagcgg	acggaacgct	gcacgccgag	gccgagatcg	1860
atgacgcggc	gccatggagc	gccgaacgcc	ccgacctgta	cgagctatcc	gtcaccctgc	1920
tcgacgcgga	cggcaaggtc	ctggagaccg	ctcgactctg	catcggcttc	cggcatgtgg	1980
ccatcgagga	cggcatcctc	aagctcaacg	gcaagcgcc	cgtgttccgt	ggcgtcaacc	2040
gccacgagtt	cgactgccgg	cgcgggccgg	ccatcaccga	agaggacatg	ctgtgggaca	2100
tccgcttcat	gaagcgccac	aacatcaacg	cgggtgcgcac	ctcgactat	ccgaaccagt	2160
cgcgctggta	cgagctgtgc	gacgaatacg	gcatctacct	gatcgacgag	accaatctgg	2220
agacccatgg	cagctggaac	agccccggcg	acatccccgt	gggaacctcc	gtccccgggtg	2280
acgacgaggg	ctggctgggc	gcgtgcatcg	accggctgga	cagcatgatc	ctgcgcgacc	2340
gcaaccatcc	cagcgtgttc	gtctggctgc	tgggcaacga	atcctacgcg	ggcgaagtcc	2400
tcaaggccat	gagcgcgcac	gcgcaccggc	ttgatccggg	tcgtcccgtc	cactacgaag	2460
gtgtcaactg	gaacctatgc	tacgacggga	tcagcgactt	cgaaagccgt	atgtacgcca	2520
agccggccga	gatccaagac	tggctcgaac	acggcgacga	acggggcgag	gcgagcaagc	2580
cgttcgtcag	ctgtgagtac	atgcatgcca	tgggcaactc	gtgcggcggg	ctgagcgagt	2640
tcatcgacct	cgaacggtac	gagcgtact	ccggcggggt	catctgggat	tacatcgacc	2700
aggggctcgt	ccagcgtctg	cccgacggga	gcgaacgcct	cagcgtcggc	ggagaatggg	2760
gcgaccgtcc	aaccgactac	gaattcgtgg	gcaacggcat	cgtgttcgcc	gaccgcacgc	2820
ccagcccca	ggcgcaggag	gtcaagcagc	tgtattcgcc	ggtaagctc	gccccgacg	2880
ggcacggcgt	gaccatcgag	aaccgcaacc	tgttcgccgg	caccgacggc	tacgtgttcg	2940
ccgcacggct	cctcgaagac	gggcatgaga	tctggcatgc	cgactaccgt	ttcgacgtgg	3000
ccgcaggaga	taccaaacac	catgacatcg	ccttcccggg	catcgacgcg	gacggggata	3060
cgcgcaagt	cacctacgag	gtcgatctcc	tgctcgccga	agccaccgca	tgggcgcccgg	3120
ccggctacga	gtcgcggttc	ggccaactca	ccggcacgct	caacccgaa	caggacatca	3180
ccgagaccag	ccatgacgac	gacggccgcg	caactcgac	gctcagccga	tggaacgccg	3240
gcatccgccc	cgacgacgag	gaaattctcc	tgtcacgcac	tcaggagggc	atcgtctcct	3300

Sequence Listing_ST25

ggaagcgcga cgaccgggaa atgggtcatcc gtcgccccga actcgtcacg ttccgccccat	3360
tgaccgacaa cgatcgcggt aaccattccg gtttcgaccg tgccgcatgg ttcgcggccg	3420
gccgatacgc catcgttaacc gaaacgaaaa tccatgaaag cgatgacggt ctcgtagcgg	3480
aataccagta cgaacttgcc gatccgaacc acacgcccgt gtccgtcact taccatgtca	3540
actccgatat gcgtatgcaa ctgaccgtcg aataccccgg gaacgccact gacatggcca	3600
gtctgccccg gttcgggtatc gaatgggagc tgcccggcga atacgatcgt ctgcgtact	3660
acggccccgg ccccgaggag acctaccgcg accgtaagca gggcggcaag ctcgcatct	3720
gggacgccac cgcaaggcg agcatggcg cgtatctcat ggtgcaggaa accggcagcc	3780
acgaggacgt ccgctggctc gaagccaccg acatccaagg ccacggattg cgcgtcacc	3840
aacgcggcga ccgtcacttc acggccagcc tgctgcccgt gaacacctac acgatcgagg	3900
ccgcgcgccg ccacgaggac ctgccc aaac cgccacaa ctacctgcgc ctgctcgcg	3960
cccagatggg cgtcgggtga gacgactcct ggggagcccc cgtccacacg gcctaccagc	4020
tgcccgccgg caggccgctc acctcgacg tgaacctcga actcatctga ccggcaacgg	4080
gcggcgccat gcaccaccat gccgcgcgcg gccccgccta cgacgcggcg atcgaggcca	4140
cgggcgctgc ggccgcggac ggcaccggcg aggaggcggt cgagcgcgcc ggccacgcgg	4200
tccacggcac caccgcccag gtcctctcgc tcatcaccaa cccgatggac gtgatctgcc	4260
gcaacatccg caccgtgcgc gagaagatgg caaccgcgcc cgacatcctc ggctgccacc	4320
tcgaaggccc gttcctcgcc ctcaagtga agggcgcgca cgattcgaac tgcccaaa	4380
acccgatgcc cgaactcatg gaccgcatgc tcgacgcctc gggcgcggac ctgcgcgccg	4440
gcaagctcgg gtgcatccgc cagatcacca tctcgacccc accgactgga ccgcccacaa	4500
cgtctggtgc gccggccgcc aggtggagta aactccttcc agcaaaatcg acgccggtgc	4560
cgcccgcttc gagacgacgt cttacgcctg aggaacgaag cttgcgcgcg gcaccagttc	4620
ggtcgtcagc aggatgtgac gacgcacccg ccgctcatgc ttcaaccat cgatcaggg	4680
ggagaacgcc atgcggggcca actccctttg atcgatcgca tacgaactca gcggcggcga	4740
cgtgtaccgg gcgatcgact ggttggtcac actcaccacg gccaaactcg cgggaacctc	4800
cacgcgcagt gcgttcaacg cctgcaacgc cccaccgcga agcacgtcgg cggccacgat	4860
caaaccatcg ggcattgctg cggcctcacg atggtcagcc accaactgct ccgcgagacg	4920
atagccgttc tccacggtga acgtgccgga cgaatacacc aatccgtccg tttccaatcc	4980
cagatgcgcg gccactgac ggaacgacag ctgcggaatg tcctcgggat agtcatgcat	5040
gcccattgat ctgcccacgc cgccgagaaa cgcgatatga ctgcggcccc cgcgatcat	5100
cgctccaag gcgtccagca tcgtctgcga cagatcggga cacacggagt cgaacaggcg	5160
cggcgccgga ttcgtgtcga tgcacacgcc atgcggggag accatatgca gggctcgag	5220
gtccgcttcg ggaaacaccg tggctccac ggtgatgaac ccatcaaact ccgttgcgcg	5280
ttccgtcaac tcgtgtatgg acaacgtgag ctggtccaat tccaacgact ccgcacgctc	5340

Sequence Listing_ST25

cgcaagaacc	ttccgcagat	cgcggaagta	cgcgctcctgc	aattcctccc	cggaacggagg	5400
cgcatccaac	accgcgatcg	cgggacggaa	cacgttgcgga	taccccatct	cctcgcacac	5460
gcgcaacaca	cgccgacgcg	tctcctcctt	gatggagaac	gacgggtcgt	tcaacaagcg	5520
tgacaccgtg	ctctgcgaca	ccccggcccc	tcccgcgact	tccttgagcg	tggccatgac	5580
atcctccccg	caaactttag	taaaggggtt	tactacagca	taaccgggga	aggcgggggt	5640
agcggcattg	gcggcggtga	agtttaccca	tgactggtag	actgcacatg	tcccggcaat	5700
aggggcaatg	catagggggg	tggcgggcat	gtgcagcaac	attcccgta	ccttacgatt	5760
cttatagcgt	gtcaggtaaa	agaattatga	ttctcaatcc	accttcggc	cgcgctgca	5820
gactcaaattg	gccatgatgc	atagcgacaa	tctctgcac	tatggataaa	cccaatccgt	5880
gatgaggtga	tgcagatccc	acatgcgtat	ttatcctatt	atcctcccct	ctgttaaaag	5940
gtgacaggaa	atcatctatc	ctcgtatcgg	aaagatccat	gccggtattg	gatatgtcta	6000
tcgcaatgca	ggactcgcct	tcgtattgcc	tgtcgttggc	taagtttatc	catacatgtg	6060
gttgagccgc	acgattatgc	tgaatggcat	tcgtaataag	gtttgcaatc	atctgtctaa	6120
ttagcagacc	atcggctagg	atatatgcat	tctccagatt	ggtatgtact	tgaactctat	6180
ctccgataag	ttccatattt	tcctgaagaa	cattgcgaat	gatctcagct	acattaactc	6240
ggctaagatc	agctcgggtt	aattgctgaa	ctttcgacaa	ttcgagcaga	tgattgacga	6300
tttcaacccc	agcatgattt	gaagccaaag	ccttttcgac	gaaaggctctg	caacgctcat	6360
cgaaaagctg	gttggtgcagc	ggaatctcca	atgcgggcca	agtggccgca	agtggatttt	6420
ttaactcatg	tgacgcgatc	gcgataaatt	ccttttcccc	actgattgcg	ctgttgagat	6480
cctttaacat	gagggtgtat	gcggatgcaa	tagtgtacgc	ctcgtcgttt	tcatatggaa	6540
taacgatagg	ttgcctttcc	aatccagcgt	cggacgcgat	aatctgagag	gccacactat	6600
tgattcttcg	ttgtgtccta	gtggcgataa	tccaagttat	tcctccagat	aatatgccga	6660
aaacaatgat	gggggctatg	cttaccgcca	atatcagatc	ccgggatttt	atgtctcctt	6720
gttccatagt	tagcgttaaa	gcacctttac	cggagtcata	cccggcagaa	acgtaatcct	6780
taccggagtc	aggaggaatg	gcttgcgaa	tcaaactatg	ttgttcacg	gcatcttctg	6840
cctgagtaaa	agattttatt	acggtcactg	tttccagttg	ccggttcacg	acataatatg	6900
tcatggcggg	caccactccg	gtaagcatga	agaacacgat	gacgatcgtg	gtgaccaatc	6960
ttcttcttgt	agaccactga	aacggtaaac	gcagtttcgg	atggctggaa	tggctcccat	7020
tcgacgaagg	atattcaggc	tttttcatga	tatgcgatat	ccttgtccgg	gaacggtttc	7080
aatgaaatca	gtgattccga	ttttcgtgcg	aatcgcgatg	attgtggtct	tgacgattcc	7140
tctcgtatga	gcgtgatcat	cctgccaaat	ctcacgatat	agacattccg	cactaatcac	7200
cgcacctcgc	gcctcaatca	gcgtcctcaa	tacggcaagt	tctcgtttcc	caaactttag	7260
ttctgcaccg	cgaaccgtga	t				7281

Sequence Listing_ST25

<211> 1052
<212> PRT
<213> Bifidobacterium bifidum

<220>
<221> PEPTIDE
<222> (1)..(1052)

<400> 2

Met Asn Thr Thr Asp Asp Gln Arg Lys Asn Gly Asp Pro Ile Val Ser
1 5 10 15

Pro Ser Ile Pro Thr Thr Ala Trp Leu Ala Asp Pro Arg Val Tyr Ala
20 25 30

Val His Arg Leu Asp Ala His Ser Asp His Ala Cys Trp Ser Arg Ser
35 40 45

Pro Val Asp Gly Glu Ser Thr Asn Leu Arg Gln Ser Leu Asp Gly Glu
50 55 60

Trp Arg Val Arg Val Glu Thr Ala Pro Thr Gly Arg Phe Pro Asp Gly
65 70 75 80

Thr Ser Asp Gly Pro Asp Trp Ile Ser Asp Val Ser Pro Leu Phe Ala
85 90 95

Ala Pro Gly Phe Asp Asp Ser Ser Phe Ser Arg Val Gln Val Pro Ser
100 105 110

His Leu Glu Thr Ala Gly Leu Leu Ala Pro Gln Tyr Val Asn Val Gln
115 120 125

Tyr Pro Trp Asp Gly His Glu Asp Pro Lys Ala Pro Ala Ile Pro Glu
130 135 140

His Gly His Val Ala Val Tyr Arg Arg Glu Phe Asp Ala Asp Gly Glu
145 150 155 160

Val Ala Gln Ala Val Arg Glu Gly Arg Pro Val Thr Leu Thr Phe Gln
165 170 175

Gly Ala Ala Thr Ala Ile Tyr Val Trp Leu Asn Gly Ser Phe Val Gly
180 185 190

Tyr Ala Glu Asp Ser Phe Thr Pro Ser Glu Phe Asp Val Thr Asp Ala
195 200 205

Ile Lys Val Asp Gly Asn Val Leu Ala Val Val Cys Tyr Glu Tyr Ser
210 215 220

Ser Ala Ser Trp Leu Glu Asp Gln Asp Phe Trp Arg Leu His Gly Leu
Page 5

Sequence Listing_ST25

225 230 235 240
 Phe Arg Ser Val Glu Leu Asn Ala Arg Pro Ala Ala His Ile Ala Asp
 245 250 255
 Leu His Ala Asp Ala Asp Trp Asp Leu Ala Thr Ser Arg Gly Ser Leu
 260 265 270
 Ser Leu Asp Val Leu Ile Asp Gly Ala Ala Asn Ala Ala Thr Val Asp
 275 280 285
 Phe Ala Leu Trp Asp Lys Asn Gly Thr Ile Val Trp His Thr Ala Thr
 290 295 300
 Lys Ala Asp Gly Thr Leu His Ala Glu Ala Glu Ile Asp Asp Ala Ala
 305 310 315 320
 Pro Trp Ser Ala Glu Arg Pro Asp Leu Tyr Glu Leu Ser Val Thr Leu
 325 330 335
 Leu Asp Ala Asp Gly Lys Val Leu Glu Thr Ala Arg Thr Arg Ile Gly
 340 345 350
 Phe Arg His Val Ala Ile Glu Asp Gly Ile Leu Lys Leu Asn Gly Lys
 355 360 365
 Arg Leu Val Phe Arg Gly Val Asn Arg His Glu Phe Asp Cys Arg Arg
 370 375 380
 Gly Arg Ala Ile Thr Glu Glu Asp Met Leu Trp Asp Ile Arg Phe Met
 385 390 395 400
 Lys Arg His Asn Ile Asn Ala Val Arg Thr Ser His Tyr Pro Asn Gln
 405 410 415
 Ser Arg Trp Tyr Glu Leu Cys Asp Glu Tyr Gly Ile Tyr Leu Ile Asp
 420 425 430
 Glu Thr Asn Leu Glu Thr His Gly Ser Trp Asn Ser Pro Gly Asp Ile
 435 440 445
 Pro Val Gly Thr Ser Val Pro Gly Asp Asp Glu Ala Trp Leu Gly Ala
 450 455 460
 Cys Ile Asp Arg Leu Asp Ser Met Ile Leu Arg Asp Arg Asn His Pro
 465 470 475 480
 Ser Val Leu Val Trp Ser Leu Gly Asn Glu Ser Tyr Ala Gly Glu Val
 485 490 495
 Leu Lys Ala Met Ser Ala His Ala His Arg Leu Asp Pro Gly Arg Pro

Sequence Listing_ST25

500

505

510

Val His Tyr Glu Gly Val Asn Trp Asn His Ala Tyr Asp Gly Ile Ser
515 520 525

Asp Phe Glu Ser Arg Met Tyr Ala Lys Pro Ala Glu Ile Gln Asp Trp
530 535 540

Leu Glu His Gly Asp Glu Arg Gly Glu Ala Ser Lys Pro Phe Val Ser
545 550 555 560

Cys Glu Tyr Met His Ala Met Gly Asn Ser Cys Gly Gly Leu Ser Glu
565 570 575

Phe Ile Asp Leu Glu Arg Tyr Glu Arg Tyr Ser Gly Gly Phe Phe Trp
580 585 590

Asp Tyr Ile Gly Gln Gly Leu Val Gln Arg Leu Pro Asp Gly Ser Glu
595 600 605

Arg Leu Ser Val Gly Gly Glu Trp Gly Asp Arg Pro Thr Asp Tyr Glu
610 615 620

Phe Glu Gly Asn Gly Ile Val Phe Ala Asp Arg Thr Pro Ser Pro Lys
625 630 635 640

Ala Gln Glu Val Lys Gln Leu Tyr Ser Pro Val Lys Leu Ala Pro Asp
645 650 655

Gly His Gly Val Thr Ile Glu Asn Arg Asn Leu Phe Ala Gly Thr Asp
660 665 670

Gly Tyr Val Phe Ala Ala Arg Leu Leu Glu Asp Gly His Glu Ile Trp
675 680 685

His Ala Asp Tyr Arg Phe Asp Val Ala Ala Gly Asp Thr Gln His His
690 695 700

Asp Ile Ala Phe Pro Asp Ile Asp Ala Asp Gly Asp Thr Arg Glu Val
705 710 715 720

Thr Tyr Glu Val Asp Leu Leu Leu Ala Glu Ala Thr Ala Trp Ala Pro
725 730 735

Ala Gly Tyr Glu Leu Ala Phe Gly Gln Leu Thr Gly Thr Leu Asn Pro
740 745 750

Glu Gln Asp Ile Thr Glu Thr Ser His Asp Asp Asp Gly Arg Ala Thr
755 760 765

Arg Thr Leu Ser Arg Trp Asn Ala Gly Ile Arg Arg Asp Asp Glu Glu
Page 7

2

2

1040

1045 Sequence Listing_ST25
1050